AI-generated · cited to primary sources · not investment advice
Shilpa Medicare (530549) Aug 2025 Filing Analysis
Does management do what it says?
Management confirmed the product was launched in Q3 (November) and is seeing steep growth on a quarter-on-quarter basis. (1 met across 1 tracked commitment)
“Received approval NorUDCA, India’s first-in-class therapy for NAFLD, revenue to start from 3QFY26”
See the full cited Management analysis of Shilpa Medicare
How durable is the business?
Regulatory standing improved as the company received an Establishment Inspection Report (EIR) from the U.S. FDA for its transdermal patch manufacturing facility, opening the U.S. market for this niche category. (2 expanding)
“I'm happy to inform everyone that in the current quarter, we have received EIR from U.S. FDA for our transdermal patch manufacturing facility, which will open opportunities in the U.S. market also for our transdermal patch facility.”
See the full cited Business Model analysis of Shilpa Medicare
Where does growth come from?
The company is accelerating its API growth through newly increased capacities for key products like UDCA and Azacitidine, with a new dedicated block for OLC expected to commercialize in FY26. (3 accelerating, 2 steady across 5 signals)
“Newly increased capacities for key products viz. UDCA, Tranexamic Acid, Azacitidine, Palbociclib and Nilotinib to contribute materially in FY26... New dedicated block for OLC expected to be commercialized in FY26”
See the full cited Future Growth analysis of Shilpa Medicare
What could break the thesis?
Margins have significantly improved to 76% (up 700 bps YoY) due to a better product mix and licensing income, suggesting that input cost pressures are currently being offset by high-value launches. (5 easing)
“Our gross margins for the quarter were at 76%, an improvement of 700 basis points compared to last year. And this improvement was mainly driven by a better product mix.”
See the full cited Risk analysis of Shilpa Medicare
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.